Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 6/20 | 0.33 |
| ▸ | ITGAV | P06756 | 5/20 | 0.33 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.33 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 3/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22167479 | 1.00 | KIFC1 (0.35) | KIFC1ITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL17468487 | 0.95 | KIFC1 (0.34) | KIFC1ITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL17532368 | 0.95 | KIFC1 (0.34) | KIFC1ITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL19695867 | 0.95 | KIFC1 (0.34) | KIFC1ITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL19695865 | 0.94 | HPGDS (0.33) | — | |
| SCHEMBL17532332 | 0.94 | PSMB2 (0.33) | KIFC1PSMB2 | |
| SCHEMBL17459567 | 0.93 | MME (0.32) | KIFC1MMEPSMB2 | |
| SCHEMBL19695848 | 0.93 | MME (0.32) | KIFC1MMEPSMB2 | |
| SCHEMBL22167454 | 0.93 | PSMB2 (0.33) | KIFC1MMEACEACE2PSMB2 | |
| SCHEMBL17532335 | 0.93 | PSMB2 (0.33) | KIFC1MMEACEACE2PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3172199-B1 | PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-07-01 | — | — | EP | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | KIFC1 4760/4885ITGB3 3314/4885ITGA2B 3336/4885 |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | KIFC1 4760/4885ITGB3 3314/4885ITGA2B 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.